Pantethine supports cardiovascular health, study shows
Highlights
- Randomized, double-blind, placebo-controlled study
- Pantethine supports cardiovascular health, including cholesterol metabolism
- Effective supplementation dosage is 600 to 900 mg/day
Summary
This randomized, double-blind, placebo-controlled study involved 32 middle-aged men and women living in North America at low- or moderate-risk of cardiovascular disease (CVD) and eligible for statin therapy based on the National Cholesterol Education Program (NCEP) guidelines.
Subjects followed a Therapeutic Lifestyle Change (TLC) diet for 4 weeks before starting the study and maintained the diet throughout a 16-week study period. The subjects were randomly assigned to take pantethine (600 mg/day from weeks 1 to 8 and 900 mg/day from weeks 9 to 16) or a placebo.
Compared to placebo, treatment significantly (P<.05) reduced total cholesterol (at 16 weeks), LDL cholesterol (at 8 and 16 weeks), and non-HDL cholesterol (at 16 weeks). A significant between-group difference in LDL cholesterol was found as early as week 8. These findings suggest that pantethine lowers CVD risk markers in people with low or moderate CVD risk.
